首页> 外文期刊>Therapeutic advances in urology. >Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy
【24h】

Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy

机译:美国癌症联合委员会第八分期系统在行前列腺癌根治术的前列腺癌患者中的验证

获取原文
           

摘要

The objective in this paper was to validate the prognostic performance of the American Joint Committee on Cancer (AJCC) 7th and 8th systems among prostate cancer patients treated with radical prostatectomy. The surveillance, epidemiology and end results (SEER) database (2006–2014) was accessed through the SEER*Stat program and AJCC 7th and 8th editions were calculated utilizing T, N and M stages, histological grade group, as well as baseline prostatic-specific antigen (PSA). Cancer-specific and overall survival analyses according to 7th and 8th editions were conducted. Moreover, multivariate analysis was conducted through a Cox proportional hazard model. A total of 72,999 patients with prostate cancer were identified in the period from 2006 to 2014. Overall survival was assessed according to AJCC 7th and 8th staging systems. The test for trend for overall survival was significant (p p versus AJCC 7th staging system in the postprostatectomy setting. This may be related to better integration of biological factors into the staging system.
机译:本文的目的是验证美国前列腺癌​​联合委员会(AJCC)第七和第八系统在行根治性前列腺切除术治疗的前列腺癌患者中的预后性能。通过SEER * Stat程序访问了监测,流行病学和最终结果(SEER)数据库(2006-2014),并使用T,N和M分期,组织学分级组以及基线前列腺肥大计算了AJCC的第7版和第8版特异性抗原(PSA)。根据第7版和第8版进行了针对癌症的总生存期分析。此外,通过Cox比例风险模型进行了多元分析。在2006年至2014年期间,总共确定了72,999名前列腺癌患者。根据AJCC第七和第八分期系统评估了总生存期。总体生存趋势的检验非常显着(在前列腺切除术后,p p与AJCC第七分期系统相比。这可能与生物学因素更好地整合到分期系统中有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号